Abbisko Therapeutics to Present Promising Phase 2 Study Results at 2025 ESMO GI Congress

Abbisko Cayman Limited ( (HK:2256) ) has issued an announcement.

Abbisko Cayman Limited announced that its subsidiary, Abbisko Therapeutics, will present updated results from a Phase 2 study of irpagratinib in combination with atezolizumab for advanced hepatocellular carcinoma at the 2025 ESMO GI Congress. The study highlights the combination’s favorable safety and promising anti-tumor activity, particularly in FGF19+ HCC patients, indicating potential advancements in treatment options for this cancer type.

The most recent analyst rating on (HK:2256) stock is a Buy with a HK$18.00 price target. To see the full list of analyst forecasts on Abbisko Cayman Limited stock, see the HK:2256 Stock Forecast page.

More about Abbisko Cayman Limited

Abbisko Cayman Limited, through its subsidiary Abbisko Therapeutics, operates in the pharmaceutical industry focusing on innovative cancer treatments. The company is developing irpagratinib, a highly-selective FGFR4 small molecule inhibitor, targeting advanced hepatocellular carcinoma (HCC) characterized by hyperactivation of the FGF19 signaling pathway.

Average Trading Volume: 6,459,189

Technical Sentiment Signal: Buy

Current Market Cap: HK$5.33B

For a thorough assessment of 2256 stock, go to TipRanks’ Stock Analysis page.